These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 16298986)

  • 41. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage.
    Svicher V; Alteri C; Artese A; Zhang JM; Costa G; Mercurio F; D'Arrigo R; Alcaro S; Palù G; Clementi M; Zazzi M; Andreoni M; Antinori A; Lazzarin A; Ceccherini-Silberstein F; Perno CF;
    Antivir Ther; 2011; 16(7):1035-45. PubMed ID: 22024519
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A virus-envelope paired competitive assay to study entry efficiency of human immunodeficiency virus type 1 in vitro.
    Schwalbe B; Hauser H; Schreiber M
    J Virol Methods; 2014 Sep; 205():91-8. PubMed ID: 24859049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonproductive human immunodeficiency virus type 1 infection of human fetal astrocytes: independence from CD4 and major chemokine receptors.
    Sabri F; Tresoldi E; Di Stefano M; Polo S; Monaco MC; Verani A; Fiore JR; Lusso P; Major E; Chiodi F; Scarlatti G
    Virology; 1999 Nov; 264(2):370-84. PubMed ID: 10562499
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies.
    Singh A; Collman RG
    J Virol; 2000 Nov; 74(21):10229-35. PubMed ID: 11024154
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Unexpected coreceptor usage of primary human immunodeficiency virus type 1 isolates from viremic patients under highly active antiretroviral therapy.
    Holtkamp N; Otteken A; Findhammer S; Miller V; Kurth R; Werner A
    J Infect Dis; 2000 Feb; 181(2):513-21. PubMed ID: 10669334
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.
    Maeda Y; Foda M; Matsushita S; Harada S
    J Virol; 2000 Feb; 74(4):1787-93. PubMed ID: 10644351
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.
    Moncunill G; Armand-Ugón M; Pauls E; Clotet B; Esté JA
    AIDS; 2008 Jan; 22(1):23-31. PubMed ID: 18090388
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
    Martín J; LaBranche CC; González-Scarano F
    J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CCR5 and CXCR4 usage by non-clade B human immunodeficiency virus type 1 primary isolates.
    Thompson DA; Cormier EG; Dragic T
    J Virol; 2002 Mar; 76(6):3059-64. PubMed ID: 11861874
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mucosal transmissibility, disease induction and coreceptor switching of R5 SHIVSF162P3N molecular clones in rhesus macaques.
    Ren W; Mumbauer A; Zhuang K; Harbison C; Knight H; Westmoreland S; Gettie A; Blanchard J; Cheng-Mayer C
    Retrovirology; 2013 Jan; 10():9. PubMed ID: 23369442
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coreceptor usage by HIV-1 and HIV-2 primary isolates: the relevance of CCR8 chemokine receptor as an alternative coreceptor.
    Calado M; Matoso P; Santos-Costa Q; Espirito-Santo M; Machado J; Rosado L; Antunes F; Mansinho K; Lopes MM; Maltez F; Santos-Ferreira MO; Azevedo-Pereira JM
    Virology; 2010 Dec; 408(2):174-82. PubMed ID: 20947116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1.
    Tscherning C; Alaeus A; Fredriksson R; Björndal A; Deng H; Littman DR; Fenyö EM; Albert J
    Virology; 1998 Feb; 241(2):181-8. PubMed ID: 9499793
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.
    Cashin K; Roche M; Sterjovski J; Ellett A; Gray LR; Cunningham AL; Ramsland PA; Churchill MJ; Gorry PR
    J Virol; 2011 Oct; 85(20):10699-709. PubMed ID: 21835796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
    Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
    J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Functional complementation of the envelope hypervariable V3 loop of human immunodeficiency virus type 1 subtype B by the subtype E V3 loop.
    Sato H; Kato K; Takebe Y
    Virology; 1999 May; 257(2):491-501. PubMed ID: 10329559
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage.
    Santos-Costa Q; Lopes MM; Calado M; Azevedo-Pereira JM
    Retrovirology; 2014 Nov; 11():99. PubMed ID: 25421818
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays.
    Van Baelen K; Vandenbroucke I; Rondelez E; Van Eygen V; Vermeiren H; Stuyver LJ
    J Virol Methods; 2007 Dec; 146(1-2):61-73. PubMed ID: 17640743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
    Means RE; Matthews T; Hoxie JA; Malim MH; Kodama T; Desrosiers RC
    J Virol; 2001 Apr; 75(8):3903-15. PubMed ID: 11264379
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction.
    Guillon C; Schutten M; Boers PH; Gruters RA; Osterhaus AD
    J Virol; 2002 Mar; 76(6):2827-34. PubMed ID: 11861850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.